Shamburg News · 8-K filed Nov 12, 2026, 8:05 AM EST

Aktis Oncology Reports Third-Quarter 2026 Financial Results and Clinical Progress

AKTS · Aktis Oncology, Inc.

  • Earnings
  • Materiality: high

Aktis Oncology reported unaudited results for the quarter ended September 30, 2026, with collaboration revenue of $3.9 million and a net loss of $29.9 million. Research and development expenses were $32.1 million and general and administrative expenses were $6.5 million. Cash, cash equivalents, and marketable securities were $492.9 million at quarter end, which the company says will fund its operating plan into 2029.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-457045.

Written from the filing by Shamburg Markets. Figures are as reported by the company.